



Announcement Summary

Entity name

PRESCIENT THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

Monday July 27, 2020

The Proposed issue is:

☒ An offer of securities under a securities purchase plan

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
PTX	ORDINARY FULLY PAID	118,181,818

+Record date

Friday July 24, 2020

Offer closing date

Monday August 17, 2020

+Issue date

Monday August 24, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

PRESCIENT THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

56006569106

1.3 ASX issuer code

PTX

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

Monday July 27, 2020

1.6 The Proposed issue is:

☒ An offer of +securities under a +securities purchase plan



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☒ No

Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

PTX : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +security code and description

PTX : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

118,181,818

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?

☒ No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?

☒ No



Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?

☒ Yes

Is the minimum acceptance unit based or dollar based?

☒ Dollar based (\$)

Please enter the minimum acceptance value

\$ 5,000

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?

☒ Yes

Is the maximum acceptance unit based or dollar based?

☒ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

\$5,000 for 90,910 shares, \$10,000 for 181,819 shares, \$15,000 for 272,728 shares, \$20,000 for 363,637 shares, \$25,000 for 454,546 shares, \$30,000 for 545,455 shares

Offer price details

Has the offer price been determined?

☒ Yes

In what currency will the offer be made?

AUD - Australian Dollar

What is the offer price per +security?

AUD 0.05500

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?

☒ Yes

Describe the scale back arrangements

If Applications are scaled back, the share allocation of Eligible Shareholders participating in the SPP will be reduced on a pro rata basis based on the size of the existing security holding of the Eligible Shareholder as at the Record Date

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes



4C.1 Date of announcement of +security purchase plan

Monday July 27, 2020

4C.2 +Record date

Friday July 24, 2020

4C.3 Date on which offer documents will be made available to investors

Monday July 27, 2020

4C.4 Offer open date

Tuesday July 28, 2020

4C.5 Offer closing date

Monday August 17, 2020

4C.6 Announcement of results

Thursday August 20, 2020

4C.7 +Issue date

Monday August 24, 2020

Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?

☒ Yes

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?

☒ No

4E.2 Is the proposed offer to be underwritten?

☒ Yes

4E.2a Who are the underwriter(s)?

Viriathus Capital Pty Ltd ACN 113 959 596

4E.2b What is the extent of the underwriting (ie the amount or proportion of the issue that is underwritten)?

\$4,000,000



4E.2c What fee, commission or other consideration is payable to them for acting as underwriter(s)?

- an underwriting fee of 3.5% of the Underwritten Amount; and
- a placement fee of 3.5% of any part of the Underwritten Amount which is paid by the Underwriter to the Company; and
- the Underwriter's reasonable costs and expenses up to a limit of \$1,000 unless otherwise approved by the Company,

4E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated.

The key terms are summarised in the offer booklet in section 4 but summarised below:

- (a) a statements in the offer document or cleansing statement is inaccurate or misleading;
- (b) drops in the market by 10% or more below the level on the business day before the date the Offer is announced (details within offer document);
- (c) regulatory investigations in relation to the offers;
- (d) removal from ASX Listing;
- (e) a director or a senior manager of a Relevant Company is charged with an indictable offence;
- (f) insolvency;
- (g) changes to the timetable greater than three days without prior written consent;
- (h) changes to the capital structure; and
- (i) other items as outlined within the offer booklet.

4E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?

☒ No

4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

☒ No

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

The funds raised from the SPP will be used to progress the Company's clinical and pre-clinical programs in both targeted cellular therapies for the development of personalised cancer approaches; general working capital and costs of the offer.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?

☒ No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

All Countries outside Australia and New Zealand

4F.3 URL on the entity's website where investors can download information about the proposed offer

<https://prescienttherapeutics.investorportal.com.au/>

4F.4 Any other information the entity wishes to provide about the proposed offer

